This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TSBX Turnstone Biologics (TSBX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Turnstone Biologics Stock (NASDAQ:TSBX) Get Turnstone Biologics alerts:Sign Up Key Stats Today's Range$0.36▼$0.3650-Day Range$0.35▼$0.3752-Week Range$0.29▼$2.42VolumeN/AAverage Volume142,319 shsMarket Capitalization$8.21 millionP/E RatioN/ADividend YieldN/APrice Target$0.45Consensus RatingReduce Company Overview Turnstone Biologics, Inc. (NASDAQ: TSBX) is a clinical-stage biopharmaceutical company pioneering next-generation viral immunotherapies for the treatment of solid tumors. The company’s proprietary platform harnesses engineered oncolytic viruses to selectively infect and lyse cancer cells while simultaneously delivering genetic payloads that stimulate a potent anti-tumor immune response. By combining direct tumor debulking with immune modulation, Turnstone aims to address cancers that have demonstrated resistance to conventional therapies. Turnstone’s pipeline includes multiple clinical-stage candidates targeting a range of solid tumor indications. Lead programs leverage distinct viral backbones engineered to carry immunostimulatory cytokines, bispecific T-cell engagers or immune checkpoint modulators. These investigational therapies are currently being evaluated in Phase 1/2 trials for hepatocellular carcinoma, pancreatic cancer and virus-associated malignancies such as HPV+ head and neck squamous cell carcinoma. Early-stage assets in preclinical development explore next-generation constructs designed to improve tumor targeting and expand the reach of the platform. Founded in 2017 and headquartered in Cambridge, Massachusetts, Turnstone Biologics completed its merger with a special purpose acquisition company in early 2021 and began trading on the Nasdaq under the ticker symbol TSBX. The company is led by an experienced management team with deep expertise in oncology drug development, virology and translational medicine. Turnstone collaborates with leading academic institutions and leverages global clinical trial networks to advance its mission of delivering durable, virus-based immunotherapies to patients with high-unmet-need tumors.AI Generated. May Contain Errors. Read More Receive TSBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TSBX Stock News Headlines$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)June 30, 2025 | globenewswire.comTurnstone Biologics Corp. Enters Merger Agreement with XOMAJune 27, 2025 | tipranks.comBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging crypto — now called “Wall Street’s preferred choice” — with tech giants like Microsoft, Google, and Amazon already using it.October 10 at 2:00 AM | Weiss Ratings (Ad)XOMA stock rises after acquisition of Turnstone BiologicsJune 27, 2025 | au.investing.comTurnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment SlumpsJune 27, 2025 | msn.comTSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to ShareholdersJune 27, 2025 | businesswire.comTurnstone Biologics Corp. (TSBX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...May 8, 2025 | gurufocus.comSee More Headlines TSBX Stock Analysis - Frequently Asked Questions How were Turnstone Biologics' earnings last quarter? Turnstone Biologics Corp. (NASDAQ:TSBX) released its earnings results on Friday, August, 8th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.08. When did Turnstone Biologics IPO? Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at a price of $12.00 per share. What other stocks do shareholders of Turnstone Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Turnstone Biologics investors own include Cara Therapeutics (CARA), JPMorgan Chase & Co. (JPM), Avino Silver & Gold Mines (ASM), Bank of America (BAC), Intel (INTC) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings8/08/2025Today10/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSBX CIK1764974 Webturnstonebio.com Phone347-897-5988FaxN/AEmployees82Year Founded2015Price Target and Rating Average Price Target for Turnstone Biologics$0.45 High Price Target$0.50 Low Price Target$0.40 Potential Upside/Downside+26.8%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-171.86% Return on Assets-128.13% Debt Debt-to-Equity RatioN/A Current Ratio3.33 Quick Ratio3.70 Sales & Book Value Annual Sales$19.31 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book0.55Miscellaneous Outstanding Shares23,140,000Free Float15,713,000Market Cap$8.21 million OptionableNot Optionable Beta1.36 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:TSBX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.